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There is growing interest in myeloid (my) dendritic cells (DC) as an alternative to monocyte-derived DC (moDC) for immuno-
therapy. However, in contrast to moDC, little is known regarding the effect of malignancy on the function, abundance or use
of intracellular signaling pathways in myDC. Understanding the molecular detail of circulating myDC is therefore important for
future use in advanced cancer. Advanced cancer patients had similar numbers of circulating myDC to cancer-free patients and
healthy individuals, and secreted similar levels of IL-1b, IL-6, IL-10, IL-12 and IL-23. However, myDC from some patients failed
to secrete the Th1-cytokine IL-12. Surprisingly, inhibiting p38 (p38i) signaling (using BIRB0796 or SB203580) markedly
increased IL-12 secretion by myDC. This is in complete contrast to what is established for moDC where inhibiting p38 ablates
IL-12. Interestingly, this was specific to IL-12, since IL-10 was suppressed by p38i in both DC types. The opposing effect of
p38i on IL-12 was evident at the transcriptional level and in both DC types was mediated through the p38-MK2 pathway but
did not involve differential phosphorylation of the distal Rsk kinase. Importantly, where patient myDC did not secrete IL-12 (or
after treatment with suppressive melanoma lysate), p38i restored IL-12 to normal levels. In contrast to p38, inhibiting the
other MAPK pathways had similar consequences in both DC types. We show for the first time the differential use of a major
intracellular signaling pathway by myDC. Importantly, there are sufficient circulating myDC in advanced cancer patients to con-
sider development of adoptive immunotherapy.
Dendritic cells (DC) govern T-cell antigen-speciﬁcity, activa-
tion and polarization and their secretion of Interleukin (IL)-
12p70 (IL-12) induces Th1 and cytotoxic T cell (CTL)
responses.1 Their role in anti-tumor immunity led to investi-
gation of monocyte-derived DC (moDC) for immunotherapy.
Circulating CD1c1 myeloid DC (myDC) are a physiological
population of human DC which do not require in vitro gen-
eration and therefore have technical advantages over
moDC.2,3 In addition, the potential immunotherapeutic bene-
ﬁts of myDC include more potent induction of T cell
responses4 and more efﬁcient chemotaxis toward T-cell che-
mokines.5–7 Whilst CD1c1 myDC share many general char-
acteristics with moDC including cross-presentation, response
to danger and priming T-cells,4,8,9 it has become increasingly
clear that they do not function in exactly the same way and
need to be studied in their own right. Key considerations yet
to be addressed are whether there are sufﬁcient myDC to use
for immunotherapy in advanced cancer patients and whether
they have normal function when isolated from the blood of
cancer patients.
In order to design a clinically effective DC therapy, the
ability to enhance Th1 polarization by increasing IL-12 secre-
tion and suppress Treg induction via a reduction in IL-10
would be advantageous. We have studied other intracellular
signaling pathways and demonstrated a novel role for the
ATM DNA repair pathway in regulation of IL-23 and Th17
polarization in myDC and moDC.10 The MAPK pathways
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are critically involved in DC cytokine secretion and their role
in determining the pattern of cytokine release after activation
has been extensively studied in moDC.11–18 In contrast to
moDC, MAPK signaling in human circulating myDC has not
yet been studied, and whether intracellular signaling is the
same in moDC and myDC is unknown. If these pathways
are to be targeted to enhance Th1/suppress Treg polarization
in the setting of a DC vaccine, it is crucial to have a full
understanding of how they function in the particular DC
subset being used.
In addition to their role for cytokine production in DC, the
MAPK pathways are of substantial current clinical interest for
direct targeting in disease. Small-molecule p38 inhibitors are in
clinical trials in cancer,19 rheumatoid arthritis,20 chronic
obstructive pulmonary disease21 and neuropathic pain,22
although the results in autoimmune disease in particular have
been disappointing. Lentiviral targeting of MAPK pathways in
DC is being investigated for the treatment of cancer23 and auto-
immune diseases.24 These studies derive from observations of
abnormalities in MAPK pathways in a range of diseases and
pre-clinical studies.25–28 Targeting the RAS-RAF-MEK-
Extracellular signal-regulated kinase (ERK) pathway with small-
molecule inhibitors is clinically beneﬁcial in BRAF-mutated
melanoma.29,30 With the explosion of interest in molecular tar-
geting, it is important to understand the potential effects of these
therapeutic strategies outside the intended target tissue.
This study identiﬁes for the ﬁrst time key differences in
function of the MAPK pathways in myDC compared with
moDC. Whilst the MEK/ERK pathway served similar roles for
cytokine production, marked differences were observed
between myDC and moDC for p38 MAPK. In particular, the
p38 pathway served a negative regulatory role for IL-12 pro-
duction in myDC in contrast to the canonical positive role in
moDC.11–13 Interestingly, this was IL-12-speciﬁc, as p38 inhi-
bition (p38i) reduced IL-10 (accepted to inhibit anti-cancer T-
cell responses) in both types of DC. In Stage 4 cancer patients,
we established that there are sufﬁcient numbers of circulating
myDC for therapeutic vaccine use. Importantly, we demon-
strated that even in myDC from advanced cancer patients that
are severely impaired in their ability to produce IL-12, p38i
restores secretion to normal levels whilst suppressing IL-10.
Appreciating the differential use of the major intracellular sig-
naling pathways in myDC has clear implications for the clinical
application of MAPK inhibitors and for the design of immuno-
therapies in oncology.
Material and Methods
Reagents
Endotoxin-free reagents were used throughout. All media were
based on RPMI 1640 with L-glutamine (Sigma Gillingham,
UK). DC medium contained vol/vol 10% fetal calf serum (FCS)
and 1% sodium pyruvate (Sigma), T cell medium vol/vol 10%
FCS, 1% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES), 1% sodium pyruvate, 1% nonessential amino acids
and 20 mM 2-mercaptoethanol (Sigma) and MM418 medium
10% vol/vol FCS (PAA Yeovil, UK). Cytokines were recombi-
nant human (rh) IL-4 (1,000 U/ml, Immunotools Friesoythe,
Germany), rh granulocyte-macropahge colony stimulating
factor (GM-CSF) (1,000 U/ml, Peprotech London, UK), rhIL-2
(50 U/ml) and rhIL-10 (Miltenyi Bergisch Gladbach, Ger-
many). Ultrapure toll-like receptor (TLR) agonists were R848
(TLR7/8, 2.5 mg/ml, Invivogen San Diego, California) and Poly
I:C (TLR3, 20 mg/ml, Sigma). T-cells were stimulated with
mouse anti-human CD3 (OKT3, 1 mg/ml, produced in house)
and CD28 (5 mg/ml, BD Pharmingen Oxford, UK). Mouse
anti-human CD1c Phycoerythrin (PE) (Miltenyi Biotech),
CD14 Fluorescein isothiocyanate, CD4 PE (both BD),
CD45RA FITC (eBioscience Hatﬁeld, UK) and CD45RO PE
(Biolegend London, UK) were used with matched isotype con-
trols. Small molecule inhibitors of MAPK (MAPKi) (UO126
Cell Signaling Boston MA, SB203580 and SP600125 Calbio-
chem Darmstadt, Germany) were used at 10 mM, BIRB0796
(Selleckchem Newmarket, UK) was used at 0.1–1.0 mM and
MK2 inhibitor III (Calbiochem) at 1–3 mM.
Human participants
Heparinized blood was obtained from volunteers after written
informed consent with ethical approval from Nottingham
University Ethics Committee and Nottingham Research
Ethics Committee 2. Melanoma and bowel cancer patients
were recruited from Oncology Outpatient Clinics at Notting-
ham University Hospitals NHS Trust. Exclusion criteria were
recent (<3 months) chemotherapy, any prior immunotherapy
or anemia.
MyDC and moDC
Peripheral blood mononuclear cells (PBMC) were separated
from heparinized blood by centrifugation over Histopaque
1077 (Sigma). MyDC were isolated using Miltenyi CD1c
myDC kit as per manufacturer instructions. Brieﬂy, B cells
were depleted (anti-CD19 microbeads) before positive selection
What’s new?
Dendritic cells (DCs) govern antigen specificity in T cells. DCs also secrete cytokines that regulate T-cell responses. This study
explores the potential of circulating myeloid dendritic cells (myDC) for cancer immunotherapy. The authors examined intracel-
lular signalling and cytokine secretion in myDCs, and found that when p38 MAPK is inhibited in these cells, IL-12p70 produc-
tion is enhanced and IL-10 is suppressed. In contrast, monocyte-derived DCs (moDCs) require p38 MAPK for IL-12p70
production. These differences in intracellular signalling indicate that immunotherapy with myDCs may induce more potent
anti-tumour immunity in combination with MAPK inhibitors.
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of CD1c1 cells (routinely >95% pure by ﬂow cytometry).
MyDC were rested for 2 hr at 37C before further treatment.
CD1c2 cells were incubated with anti-CD14 microbeads (Mil-
tenyi), CD141 monocytes (>95% pure) selected and resus-
pended at 0.5 3 106/ml in DC medium, IL-4 and GM-CSF.
Half-volume medium/cytokines were added on day 3 and
immature moDC harvested at day 5–6.
In vitro stimulation
Immature DC (104/well) were plated in DC medium with GM-
CSF. GM-CSF was required for viability of myDC, and
included with moDC for direct comparison. The presence of
GM-CSF did not alter cytokine production by moDC, nor did
it alter the effect of MAPKi in moDC (not shown). DC were
treated with MM418 tumor-derived lysate (7.5 3 105 cells/ml)
for 1 hr, MAPKi for 1 hr then poly I:C/R848 for 24 hr. To
investigate the role of DC-derived IL-10 in regulation of IL-12,
rhIL-10 was added (0.1–1.0 ng/ml) 4 hr after TLR stimulation
(based on published data regarding timing of DC secretion of
IL-10). Supernatants were harvested and assayed by ELISA for
IL-12p70 (BD biosciences), IL-23 (eBioscience), IL-1b, IL-10
(both R&D Abingdon, UK) and IL-6 (Immunotools).
Preparation of tumor derived lysate
MM418 cells were seeded into a 10-layer factory ﬂask (Corning
Costar Amsterdam, The Netherlands), harvested by trypsiniza-
tion after 3 days, washed and resuspended at 1 3 107/ml in
RPMI 1640. Lysate was prepared by ﬁve cycles of freeze-thaw
as previously described.18 Mycoplasma testing was negative.
Quantitative PCR
MyDC and moDC were plated in DC medium with GM-CSF
(105/well in 48-well plates) and stimulated with poly I:C/
R8486 pre-treatment with SB203580 for 1 hr. At 12 hr, cells
were harvested into cold PBS, RNA isolated (Nucleospin RNAII
kit, Macherey-Nagel D€uren, Germany) and cDNA prepared
(GoScript Reverse Transcription system, Promega Madison,
WI). Taqman quantitative PCR was carried out for IL12A,
IL12B and IL23A with TOP1 as housekeeping gene (Applied
Biosystems Paisley, UK, TOP1 Hs00243257_m1, IL-12A/IL-
12p35 Hs00168405_m1, IL-12B/IL-12p40 Hs00233688_m1, IL-
23A/IL-23p19 Hs00372324_m1), with Mastermix (Primer
Design Southampton, UK) on a Stratagene MX3005P and ana-
lyzed with Stratagene software. PCR conditions were 10 min/
95C then 50 cycles of 15 sec/95C and 60 sec/60C. Quantiﬁca-
tion was done by ddCT method where dCT5 (gene of interest
CT)2 (TOP1 CT), ddCT calculated with poly I:C/R848 as refer-
ence condition and fold change in gene expression5 22ddCT.
Between 450–690 ng of RNA was obtained from 105 DC per
condition, with a 260/280 ratio of 1.7–2.0. Efﬁciency of ampliﬁ-
cation of all genes was >90%.
Polarization of naive T cell responses
DC culture supernatants were generated from 105 cells stimu-
lated with poly I:C/R8486 SB203580. At 12 hr, cells were
washed to remove TLR agonists and p38i, and fresh medium
added. Supernatants were harvested at 24 hr. Cell-free
“mock” supernatants were generated to control for carry-over
of TLR agonists/p38i. Na€ıve T cells (CD41CD45RA1) were
isolated using CD41 T cell isolation kit II and CD45RA
microbeads (Miltenyi) (purity> 95%). T cells (2 3 105/well)
were cultured with IL-2 in plates coated with anti-CD3
(1 mg/ml) with 25% DC culture supernatant and anti-CD28
(5 mg/ml). On day 5, cells were harvested and rested for 3
days. Cells were re-stimulated (2 3 105/well) with anti-CD3/
CD28/IL-2 and Golgi-Plug (BD Pharmingen). After 20 hr,
cells were ﬁxed (0.5% formaldehyde), permeabilized (Perm
Buffer, Biolegend) and incubated with mouse anti-human
Interferon (IFN)g AF647 (BD Pharmingen), IL-17 FITC
(eBioscience) and rat anti-human IL-10 PE (BD Pharmin-
gen). CompBeads (Beckman Coulter High Wycombe, UK)
were used for compensation and ﬂuorescence-minus-one
(FMO) controls with matched isotypes were used.
Western blotting
MoDC (106/well, 12-well plates) and myDC (105/well, 96-
well plates) were plated in DC medium containing GM-CSF.
For experiments directly comparing moDC and myDC, cells
were plated at 105/well in 96-well plates. Cells were rested for
2 hr, treated with MAPK inhibitor for 1 hr, stimulated with
Poly I:C/R848 then harvested, washed and lysed in RIPA
buffer (Sigma) containing protease inhibitor cocktail, phos-
phatase inhibitor cocktail 2 and 3 and Benzonase endonucle-
ase (all Sigma) on ice for 1 hr. Debris was removed by
centrifugation and samples frozen at 220C.
Proteins were resolved by electrophoresis in 10% Tris/gly-
cine gels or 4–12% Tris/glycine gradient gels (Novex Paisley,
UK) and transferred onto nitrocellulose. Membranes were
blocked with 5% milk (wt/vol) in PBS-0.1% (vol/vol) Tween
20 for 1 hr, probed with primary antibodies overnight at 4C
and secondary antibodies for 1 hr at room temperature in
1% milk (wt/vol) in PBS-0.1% (vol/vol) Tween 20. Primary
antibodies were rabbit anti-human phospho-MK2(T334)
(#3007), phospho-p38(T180/T182) (#4511), phospho-ERK1/
2(T202Y204) (#9101), phospho-Rsk(T359/S363) (#9344),
phospho-Rsk(T573) (#9346), phospho-Rsk(S380) (#9335) and
total Rsk(#9355) (Cell Signaling Technology) and mouse
anti-human b-actin (Sigma). Binding of secondary antibodies
(infrared-dye conjugated (Licor Lincoln, Nebraska): donkey
anti-rabbit-800 and anti-mouse-680) was detected by Licor
Odyssey. For semi-quantitative analysis, Odyssey software
was used and intensity normalized to loading control.
Whole blood DC enumeration assay and flow cytometry
300 ml heparinized whole blood was incubated with control
or active cocktail of antibodies for 15 min at room tempera-
ture. Control cocktail contained mouse anti-human CD19
PECy5 (BD), CD14 PECy5 (Beckman Coulter), IgG1 FITC
(Miltenyi) and IgG2a PE (Miltenyi), active cocktail contained
CD19 PECy5, CD14 PECy5, CD303 FITC (Miltenyi) and
CD1c PE (Miltenyi). 300 ml Cal-Lyse (Invitrogen) was added
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and incubated for 10 min, followed by 3 ml distilled water
and incubation for 5 min. Cells were pelleted by centrifuga-
tion, resuspended in ﬂow cytometry (FACS) buffer, ﬂowcount
ﬂuospheres (Beckman Coulter) added for absolute enumera-
tion and at least 106 events acquired. Comp-beads (BD) were
used to set compensation. Optimization and validation of
protocol was carried out to ensure reproducibility prior to
enumeration of patient DC.
Statistics
Cytokine levels are presented as mean6 standard deviation
and parametric tests were used where possible with transfor-
mations to achieve normality attempted before non-
parametric tests used. For analysis of MAPKi on healthy
donor cytokine levels, drug-treated cytokine levels are
expressed as fold change compared to TLR agonist alone and
myDC and moDC compared by one-way ANOVA with Dun-
netts post-test correction. For patient data, cytokine analysis
was done after square root transformation to achieve normal-
ity (conﬁrmed by Komogorov–Smirnov test). Baseline cyto-
kine was compared using one-way ANOVA with Bonferroni
correction of p values. MAPKi and tumor derived lysate
(TDL) effect was analyzed using two-tailed paired students’
t-test with Bonferroni correction. Combined TDL and
SB203580 effect on IL-12 was assessed using repeated meas-
ures ANOVA with Bonferroni post-test. Circulating DC
counts between groups was compared using unpaired two-
tailed students’ t-test with Welch’s correction for unequal
variances. On all ﬁgures *p< 0.05, **p< 0.005.
Results
Advanced cancer patients have normal numbers of DC
To determine whether circulating human myDC from cancer
patients are a potential therapeutic option for immunotherapy,
we established the baseline number and function of DC in
patients with fully resected and advanced (Stage 4) cancer.
Patient characteristics are shown in Table 1. The staining proto-
col and analysis strategy were optimized on healthy donors
(gating strategy Supporting Information Fig. 1A). Validation
experiments and analysis demonstrated reproducible staining
and gating (Supporting Information Figs. 1B and 1C). Circulat-
ing myDC and plasmacytoid DC numbers (Fig. 1a) in advanced
cancer patients (n5 9) were the same as patients with fully
resected cancer (n5 8) (p5 0.89 and p5 0.45, respectively)
and healthy donors from optimization experiments.
DC from advanced cancer patients secrete normal levels of
cytokines
Recent work has shown that dual TLR activation of DC is far
more effective at inducing cytokine secretion than single
Table 1. Patient demographic and disease-specific details
Fully resected Stage 4
Number 9 9
Age (years, median (range)) 57 (35–65) 63 (55–85)
Sex (male:female) 7:2 5:4
Stage of disease at original diagnosis
Stage 1 2 0
Stage 2 4 5
Stage 3 3 0
Stage 4 0 4
Time since primary resection (months, median (range))1 37 (1–75) 30 (0–82)
Time since metastatic disease diagnosed (months, median (range)) n/a 6 (1–18)
Sites of metastatic disease present2 n/a
Subcutaneous 3
Lung 6
Liver 7
Lymph node 5
Other3 2
Previous treatments
Dacarbazine 0 3
Capecitabine/5FU1 oxaliplatin 0 2
Radiotherapy 0 1
1Primary tumor not resected for two patients in Stage 4 group.
2All Stage 4 patients had >1 site of metastatic disease.
3Other: 1 patient with brain metastases and retroperitoneal metastases, 1 patient with spleen metastases.
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TLR6 IFNg or cytokine cocktails.8,31 Combinations including
a TLR7/8 agonist are key to this effect, and therefore poly I:C
(TLR3) and R848 (TLR7/8) stimulation was used throughout.
There was no signiﬁcant difference between baseline cytokine
production between healthy donors and fully resected or
advanced cancer patients for any of the cytokines measured for
myDC or moDC (Fig. 1b) except for IL-1b between healthy
and resected patients for myDC. However, whilst as a group
the cytokine production from Stage 4 patients’ myDC was nor-
mal (Fig. 1b, top), some patients exhibited markedly reduced
cytokine levels, particularly for IL-12.
Role of MAPK pathways for cytokine production by human
DC
There is a paucity of work concerning intracellular signaling
pathways in myDC. Because of the increased clinical use of
kinase-inhibitors and emerging immunotherapeutic interest in
myDC, we investigated the function of MAPK pathways for
cytokine production using healthy donors. In agreement with
previous studies,11–13 the p38 pathway was crucial for IL-12
production by moDC with secretion substantially suppressed
upon p38 inhibition (p38i) [Fig. 2a(i,ii)]. In marked contrast,
the p38 pathway in myDC was a potent repressor of IL-12 as a
pronounced increase in cytokine secretion was observed fol-
lowing p38i. Despite the common p40 subunit, p38 did not
regulate IL-23 in either DC type [Fig. 2a(i,ii)]. IL-6 and IL-1b
were similarly not regulated by p38; however, it positively regu-
lated IL-10 production in both moDC and myDC.
In contrast to p38, myDC and moDC responded similarly
to inhibition of the MEK-ERK pathway [Fig. 2a(i,ii)] although
differences in the magnitude of effect were evident. MEK-ERK
had no role in either DC type for IL-12 but was required for
IL-1b, IL-23 and IL-10 production. In myDC, the c-Jun N-ter-
minal kinase (JNK) pathway played no role for most cytokines
studied. Inhibition with SP600125 suggested that JNK was
repressive for IL-23. Conversely, in moDC JNK appeared to
play a greater role, as SP600125 suppressed production of IL-
12, IL-10 and IL-1b.
An alternate p38i, BIRB0796, was used to conﬁrm that
the effects observed were due to differential utilization of
p38, and not off-target effects of SB203580. At 0.1 mM,
BIRB0796 inhibits p38a and b without known off-target
effects32 whilst at 1.0 mM it also inhibits p38g and d, with
some effect on JNK2. In myDC, BIRB0796 (0.1mM) produced
a similar increase in IL-12 production to that seen with
SB203580 (Fig. 2b). In moDC, BIRB0796 (0.1 mM) halved IL-
12 production, with further suppression at 1.0 mM (Fig. 2b).
Whilst BIRB0796 did not suppress IL-12 from moDC as
much as SB203580, the differential effect on IL-12 production
between myDC and moDC was similar.
Loss of IL-10 is not responsible for myDC IL-12 production
following p38i
IL-10 can inhibit IL-12 production33 and we observed that
p38-inhibited moDC retained some IL-10 secretion, whilst
p38-inhibited myDC did not. We therefore conﬁrmed that
loss of IL-10 secretion was not responsible for enhanced IL-
12 after p38i in myDC. IL-10 production by DC is ﬁrst
detected 4 hr after TLR stimulation, so IL-10 was added to
p38-inhibited, activated myDC at this time point, at concen-
trations typically secreted in our experiments. Although there
was some suppression of IL-12, levels remained substantially
higher than TLR-stimulation alone (Fig. 2c) in contrast to
the ablation of IL-12 in p38i moDC.
Figure 1. Number and baseline function of cancer patient DC. (a) MyDC (CD1c1) and plasmacytoid DC (pDC) (CD3031) were enumerated in
heparinized whole blood from fully resected (n58, open circles) and Stage 4 (n59, filled circles) cancer patients using Countbeads to
enable direct absolute quantification. Shown is cells 3 104/ml for each patient and bar at mean for the group. (b) MyDC and moDC from
healthy donors (n59, crosses), fully resected (n57 myDC, n56 moDC, open circles) and advanced cancer patients (n59 myDC, n58
moDC, filled circles) were stimulated in triplicate with poly I:C/R848 for 24 hr and cytokine production analyzed by ELISA. Shown is mean
cytokine production for each donor with bar at median for the group.
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Opposing role of p38 is mediated through MK2
Using a small molecule inhibitor of MK2 we conﬁrmed
the role of this molecule in the opposing p38 effect. Block-
Figure 2. Role of MAPK pathways in DC cytokine secretion for healthy donors. (a) MyDC and moDC were stimulated with poly I:C/R848 1 hr
after pre-treatment with inhibitors targeting p38 (SB203580), MEK (UO126) or JNK (SP600125). After 24 hr, cytokine production was deter-
mined by ELISA. (i) Absolute cytokine levels for a representative donor of four, open bars5myDC, filled bars5moDC. (ii) Summary of fold
change in cytokine production for each drug compared to poly I:C/R848 alone for four independent donors, open circles5myDC, filled cir-
cles5moDC. (b) DC were treated and analyzed as in (a) but with the alternate p38 inhibitor BIRB0796 compared to SB203580 or no drug.
Shown is one representative donor of three. (c) MyDC were treated as in (a) with addition of rhIL-10 at 4 hr after TLR stimulation. Shown is
one representative donor of two. (d) MyDC (open circles) or moDC (filled circles) were treated with the indicated concentrations of the p38
inhibitor BIRB0796 or MK2 inhibitor III for 1 hr prior to TLR (poly I:C/R848) stimulation and analysis as in (a). Shown is fold change com-
pared to no drug for three independent donors. Statistical significance is between myDC and moDC for each drug dose. (e) DC were stimu-
lated with poly I:C/R848 with or without pre-treatment with p38 inhibitor SB203580 (10 mM) for 1 hr. Quantitative PCR was used to
measure expression of IL-12A/p35 (i), IL-12B/p40 (ii) and IL-23A/p19 (iii) at 12 hr after TLR stimulation and standardized to the TOP-1
gene. Fold change is relative to poly I:C/R848 for each donor. Data are given for three independent donors comparing myDC (open circles)
and moDC (filled circles). In all parts, bars are mean of experimental triplicate for a donor6SD. * p<0.05, ** p<0.005, NS5 non-
significant.
ade of MK2 reduced IL-12 secretion by moDC [Fig. 2d(i)]
and increased IL-12 from myDC, whilst IL-10 decreased in
both DC types [Fig. 2d(ii)]. Thus, by blocking the p38
pathway at two different levels, we conﬁrmed that it exerts
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opposing roles in myDC and moDC, and established a
role for MK2.
Differential IL-12 gene transcription upon
p38 inhibition
Having established opposing roles for the p38 pathway in
moDC and myDC, we determined whether this was tran-
scriptionally regulated. It was previously established that peak
transcription of all IL-12 subunits occurs 8–12 hr after TLR
stimulation. Furthermore, alterations in IL-12 secretion are
typically mediated through changes in peak transcription
level rather than transcriptional kinetics, irrespective of TLR
agonist.8,18,34,35 Our previous study established TOP1 as a
stable housekeeping gene in moDC35 and this was conﬁrmed
in myDC (Supporting Information Fig. 2). There was mini-
mal expression of p35, p40 and p19 by immature DC (Fig.
2e). As expected, TLR stimulation induced a marked increase
in p19, p35 and p40 mRNA in both DC types. Blockade of
p38 in moDC decreased p35 mRNA, with minimal change in
p40. In complete contrast, blockade of p38 in myDC resulted
in a pronounced increase in both p35 and p40 mRNA. The
level of p19 mRNA was only moderately increased in both
DC types following p38i.
Differential effect of p38 on Th1-polarization
The impact of differential p38 usage on Th-responses was
determined by priming na€ıve CD41 T-cells in the presence
of cytokine-containing supernatant from p38i myDC or
Figure 3. The p38 MAPK plays a differential role in Th1 polarization by myDC and moDC in healthy donors. The effect of differential cyto-
kine production on polarization of na€ıve Th responses was determined by co-stimulating na€ıve CD41CD45RA1 T cells through CD3/CD28
in the presence of 25% supernatant from immature DC (Imm), DC treated with poly I:C/R848 (-p38i) or DC treated with p38 inhibitor
SB203580 (10 mM) (1p38i) 1 hr prior to treatment with poly I:C/R848. Rested T cells were re-stimulated with aCD3/aCD28 for 20 h. (a)
Flow cytometry plots of intracellular cytokine staining for IFNg, IL-17 and IL-10 for two independent donors. Debris and dead cells were
gated out using FS/SS and empty fluorescent channels prior to gating for IFNg1 (AF647), IL-101 (PE) and IL-171 (FITC). (b) Summary of %
positive events for IFNg, IL-17 and IL-10 for two donors for myDC (open bars) and moDC (filled bars). Dotted line shows the % positive
events obtained following aCD3/aCD28 stimulation alone in the presence of blank medium without DC-derived cytokines.
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moDC. Mature myDC and moDC were equally effective at
generating Th1 responses (Fig. 3). In keeping with the loss of
IL-12, inhibition of p38 in moDC reduced Th1 responses to
baseline levels. In contrast, p38i myDC effectively generated
Th1 responses. The effect on Th-17 polarization was more
subtle and there was no effect on Treg polarization (IL-10).
Importantly, cell-free “mock supernatants,” used to control
for carry-over of TLR agonists and MAPK inhibitors, showed
no difference to aCD3/aCD28/IL-2 alone (Supporting Infor-
mation Fig. 3).
P38 activates Rsk via MK2 in human DC
Having established that the differential effect of p38 signaling
was mediated via MK2, we searched for candidate mecha-
nisms. In murine DC, Watts and coworkers described a unique
mechanism of Rsk phosphorylation by p38-MK2, where block-
ade of both p38 and ERK was required to fully prevent Rsk
activation upon TLR stimulation [Fig. 4a(i)],36 in contrast to
all other cell types where Rsk is activated exclusively through
MEK-ERK [Fig. 4a(ii)]. This is important as GSK3b, a down-
stream target of Rsk, is involved in IL-10 and IL-12 regulation
[Fig. 4a(iii)].37 To date this p38-MK2-Rsk link has not been
Figure 4. Comparison of intracellular signaling in myDC and moDC
after TLR stimulation and effect of blockade of MAPK pathways in
healthy donors. (a) MAPK/Rsk/GSK3b signaling. (i) Activation of Rsk
by both ERK and p38 following TLR ligation in murine splenic and
bone-marrow derived DC (arrow5 activation), (ii) Signaling down-
stream of ERK and p38 in all other cells after TLR ligation where Rsk
is only activated by ERK, (iii) Rsk drives GSK3b from the active form
(GSK3b*) to the inactive form (GSK3b) with downstream effects on
IL-12p70/IL-10 secretion, (iv) Sequence of phosphorylation/activa-
tion of Rsk by phospho-ERK (p-ERK) and phospho-p38 (p-p38). (b)
Timecourse of MK2 activation following TLR stimulation in myDC and
moDC. Donor-matched myDC and moDC (105) were stimulated with
poly I:C/R848 for the indicated times before Western blotting. To
allow cell-for-cell comparison between myDC and moDC, entire sam-
ples were used in a single Western blot and probed for phospho-
MK2 (p-MK2) with b-actin as a loading control. Infrared secondary
antibodies were used to allow for semi-quantitative analysis normal-
ized to loading control. (i) Scanned images for one donor of two. (ii)
Normalized p-MK2 for two donors, open circles5myDC, filled cir-
cles5moDC, dotted line5 upper p-MK2 band, solid line5 lower p-
MK2 band. (c) Effect of blockade of p38 or MEK on MK2 activation
following TLR stimulation in moDC. MoDC were pre-treated with p38
inhibitors SB203580 10 mM (S), BIRB0796 (B) 0.1 or 1.0 mM or MEK
inhibitor UO126 10 mM (U) for 1hr followed by poly I:C/R848 stimula-
tion for 30 min then Western blotted for p-MK2 with b-actin loading
control as in (b). Shown are scanned images for three independent
donors and graphs of normalized p-MK2 (gray bars5 upper p-MK2
band, black bars5 lower p-MK2 band). (d) Effect of blockade of p38,
MEK or both on ERK, p38 and Rsk activation in moDC. MoDC were
treated and analyzed as in (c) for phospho-ERK 1/2 (p-ERK 1/2),
phospho-p38 (p-p38), phospho-Rsk (p-Rsk, T359/S363, T573 and
S380 residues) with total Rsk as loading control. Pre-treatment was
with p38 inhibitor BIRB0796 1.0 mM (B), MEK inhibitor UO126 10 mM
(U) or both (BU). Shown are scanned images for three independent
donors and graphs of normalised p-RskSer380 for each donor. (e)
Effect of blockade of p38, MEK or both on activation of MK2 and Rsk
at Ser380 in myDC. MyDC (three donors) were treated, harvested and
analyzed as in (c) for p-MK2 and p-RskS380 with b-actin as loading
control. Pre-treatment was with p38 inhibitor BIRB0796 1.0mM (B),
MEK inhibitor UO126 10mM (U) or both (BU).
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demonstrated in human DC and we hypothesized that its
absence in human moDC could account for our ﬁndings.
In order to study signaling downstream of p38 we ﬁrst
established the time-course of MK2 activation. Immature
myDC and moDC did not express phospho-MK2 [Fig.
4b(i,ii)], however MK2 phosphorylation was induced within
15 min of poly I:C/R848 treatment. In moDC, phospho-MK2
levels plateaued after 15 min, and returned to near baseline by
1 hr. In myDC, MK2 phosphorylation peaked at 30 min before
decreasing. Although the absolute level of MK2 activation per
cell was greater in moDC than myDC [Fig. 4b(i)], when cor-
rected for cell size using b-actin [Fig. 4b(ii)], myDC appeared
to have more prominent MK2 activation than moDC.
We conﬁrmed that the inhibitors were blocking downstream
p38 signaling by measuring MK2 phosphorylation in moDC
(Fig. 4c). Treatment with SB203580 or BIRB0796 1.0 mM pre-
vented TLR-induced MK2 phosphorylation, whereas 0.1 mM
BIRB0796 did not fully inhibit MK2 activation. As expected,
MEKi did not affect phospho-MK2 levels (Fig. 4c) or p38 activa-
tion (Fig. 4d) but ablated ERK phosphorylation (Fig. 4d).
ERK sequentially phosphorylates Rsk at multiple residues
before downstream signaling occurs, whilst p38 leads directly
to phosphorylation of the S380 residue in DC, bypassing ear-
lier steps [Fig. 4a(iv)].36 RskS380 phosphorylation is the
penultimate step before downstream signaling occurs and is
the point at which p38 and ERK activation of Rsk converge
in murine DC. Poly I:C/R848 induced phosphorylation of
ERK, p38 and Rsk at all residues studied (Fig. 4d). Inhibition
of p38 increased ERK and Rsk phosphorylation at all residues
(presumably due to loss of negative feedback). Rsk phospho-
rylation at T359/S363 and T573 was prevented by UO126, in
keeping with the sequence of phosphorylation events.36
Residual phosphorylation of RskS380 remained following
UO126 treatment, and this was reproducibly (but subtly) fur-
ther reduced by BIRB0796 (Fig. 4d).
In human myDC, we found that TLR-dependent phos-
phorylation of MK2 and RskS380 was similar to moDC (Fig.
4e). BIRB0796 prevented MK2 phosphorylation but increased
phospho-RskS380. The residual level of phospho-RskS380
after MEKi was small, and whilst it reduced further with
simultaneous p38i, this effect was subtle. Importantly, there
was no difference in the pattern of RskS380 phosphorylation
between moDC and myDC. Nevertheless, we demonstrate for
the ﬁrst time that the p38-MK2-Rsk signaling link exists in
human DC, though p38 appeared to play a much lesser role
in Rsk activation than in murine DC.
P38 inhibition permits normal IL-12 secretion in myDC
from advanced cancer patients
Having established a differential role for the p38 pathway in
healthy donor DC IL-12 production, we explored whether this
still applied in advanced cancer patients. We found that p38i
(SB203580) was still able to enhance IL-12 and suppress IL-10
in advanced cancer patients (Fig. 5a, p5 0.0015 for IL-12,
p5 0.0025 for IL-10) without affecting other cytokines (not
shown). Importantly, in those patients with undetectable base-
line secretion, p38i increased IL-12 production to at least nor-
mal baseline levels.
Melanoma lysate suppresses IL-12 in myDC; restoration by
p38i
Previously, we showed that exposure of moDC to melanoma
TDL impaired IL-12 and Th-1 responses.18 Since TDL is
used for antigen loading in DC vaccination protocols, we
established whether cancer patient myDC were similarly sus-
ceptible. In all cancer patient myDC treated with melanoma
TDL, suppression of IL-12 was seen (Fig. 5b). Levels of other
cytokines were less affected, though there was some suppres-
sion of IL-23, IL-1b and IL-6. Treatment with p38i
(SB203580) prior to TDL pulsing restored the ability of
myDC to secrete IL-12 in 6/8 cancer patients and still sup-
pressed IL-10 in all donors (Fig. 5c). Thus, enhancement of
IL-12 production in myDC due to p38 inhibition is potent
enough to overcome the severely suppressive effects of TDL
treatment, at the same time as continuing to suppress IL-10
secretion.
Discussion
We demonstrate that cancer patients have sufﬁcient numbers
of myDC to be a viable immunotherapy option. Several stud-
ies have enumerated circulating DC with mixed ﬁndings,
some showing depressed number in advanced cancer and
others not,38–42 leaving this question unresolved. It has previ-
ously been difﬁcult to accurately and directly quantify circu-
lating DC but the identiﬁcation of speciﬁc markers and
development of reagents allowing direct enumeration make
accurate quantiﬁcation possible. In this study with a limited
number of patients, there were sufﬁcient myDC to harvest
for cellular therapy, with no difference between resected and
Stage 4 groups.
Cytokine secretion was also normal in the majority of
patients. To our knowledge, there has been no previous study
of the cytokine proﬁle of puriﬁed cancer patient myDC, elim-
inating potential modifying effects of other cell types as
would be the case with un-puriﬁed cells. We describe for the
ﬁrst time that the p38-MK2 pathway negatively regulates IL-
12 in human myDC. This contrasts with the established posi-
tive role for p38 in moDC for IL-12. Our ﬁndings have
implications for the utilization of myDC in cancer immuno-
therapy and for use of p38i in cancer and autoimmunity. We
demonstrated that enhancement of IL-12 after p38i occurs in
myDC from advanced cancer patients, including in those
with severely impaired cytokine production. This negative
role for p38 in myDC was surprising, given its conventionally
accepted role in inﬂammation and the fact that moDC rely
on p38 for IL-12 and consequent Th1 polarization.11–14 More
recently, however, it has been shown that p38 signaling can
lead to anti-inﬂammatory responses43 and that the require-
ment for p38 during induction of inﬂammation is tissue- and
stimulus-speciﬁc.44 We obtained similar results with two
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selective p38 inhibitors, SB203580 and BIRB0796, and an
MK2 inhibitor further conﬁrmed the p38-dependence of this
observation.
The differential involvement of the link allowing p38 to
activate Rsk (mediated through MK2)36 could have accounted
for the opposing roles of p38 in myDC and moDC. However,
the pattern of Rsk phosphorylation with p38i, MEKi or dual
blockade was similar in both DC types, discounting this as
the mechanism. It would appear that the p38-Rsk signaling
link is less important in human DC than murine DC, as only
a small amount of Rsk activity remained when MEK-ERK
was blocked and further reduction with both inhibitors was
small. MK2 has multiple downstream ligands, including
HSP27, LSP1, CREB, ATF1, SRF, tyrosine hydrolase and
TTP45 and is involved in a variety of cellular processes. Other
than the p38-MK2-Rsk-GSK3b candidate mechanism elimi-
nated in this study, a review of the literature does not reveal
any alternate mechanisms to explore. Further work to estab-
lish the down-stream targets of MK2 responsible for the
opposing effects on IL-12 production between myDC and
moDC will require detailed analysis of transcription factor
binding to the differentially affected IL12A gene.
Whilst the decrease in IL-12 from moDC after p38i sup-
pressed Th1 polarization, the increase in IL-12 in myDC did
not further induce Th1 responses in healthy donors. It could
be that levels of IL-12 were already optimal, or IL-10 may
play a role. IL-10 is secreted earlier than IL-12, and the
experimental procedure requires removal of TLR agonists/
drugs to prevent their direct impact on T-cells. As the time-
frame for washing cells overlapped with secretion of IL-10
any beneﬁcial effect of suppressing IL-10 may not be evident
in the T-cell stimulations. In patients with severely impaired
IL-12 production, p38i restored secretion to normal and it is
possible that p38i could recover deﬁcient Th1 polarization in
these patients. Due to restrictions on venepuncture (hence
leucocytes) in our advanced cancer patients, it was not possi-
ble to undertake Th1 polarization studies. However, this will
form an important part of our pre-clinical study and the acti-
vation of T-cell responses by DC:T-cell co-cultures will be
determined.
Treatment of cancer patient myDC with TDL suppressed
IL-12. Firstly, this showed that the Stage 4 patients in this
study were not “resistant” to the suppressive effects of tumor,
Figure 5. Effect of melanoma lysate with or without p38 inhibitor
on cytokine production by myDC from cancer patients. (a) MyDC
(n57) from advanced cancer patients were treated in triplicate
with p38 inhibitor SB203580 prior to poly I:C/R848. At 24 hr cyto-
kine secretion was analyzed by ELISA. Shown is mean secretion of
IL-12p70 and IL-10 for each patient plotted separately with poly
I:C/R848 alone and with pre-treatment with MAPK inhibitor. (b)
MyDC from fully resected (open circles, n57) and Stage 4 (filled
circles, n58) cancer patients were treated for 1 hr with MM418
TDL before stimulation for 24 hr with poly I:C/R848. Cytokine
secretion as a percentage remaining compared to stimulation with-
out pre-treatment with TDL was calculated for each donor. (c)
MyDC (individual symbols for each patient, n58) from advanced
and fully resected cancer patients were treated as in (b) but with 1
hr pre-treatment with p38 inhibitor SB203580 prior to TDL treat-
ment and TLR stimulation. Cytokine production (IL-12p70 and IL-
10) for each condition for each donor is plotted. p<0.05 (*) and
p<0.005 (**).
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but rather that their cells had not been signiﬁcantly impaired
in vivo since their baseline cytokine secretion was normal.
Secondly, it conﬁrmed our previous observations regarding
the detrimental effect of freeze-thaw TDL as an antigen
source.18 TDL is attractive since it provides multiple antigens
and is not restricted to speciﬁc HLA types. Recent work has
focused on generating more immunogenic lysates using heat-
shock46 or radiation47 prior to lysis or the conjugation of
virus-like particles to lysate before DC loading,48 but our
study conﬁrmed that conventional freeze-thaw TDL is sup-
pressive and thus should be treated with caution as an anti-
gen source.
Our study has important implications for the efﬁcacy of
p38i currently being tested in autoimmune/inﬂammatory
conditions. If p38i in vivo mirrors the observed ex vivo effects
then systemic administration of p38i may increase IL-12 pro-
duction, contrary to the intended anti-inﬂammatory effect.
That MK2 blockade produced a similar cytokine proﬁle in
myDC as p38i raises the possibility of targeting MK2 to sup-
port Th1 responses. Clinical use of p38i has been hampered
by side effects of liver toxicity and rashes, which may be due
to off-target effects on other pathways, or to blockade of all
downstream functions of p38. In order to alter myDC IL-12
production and hence enhance Th1 polarization it may be
sufﬁcient to block only MK2, avoiding effects on other facets
of p38 signaling. Further work is required to explore in more
detail the effects of MK2i on myDC. In cancer, p38i are
being tested for their direct anti-tumor effect19 and our
observations raise the possibility of combining systemic p38i
with targeted immunotherapeutic approaches.
Using whole peripheral blood as a source may not yield
adequate cell numbers as 500 ml would typically yield 1.5 3
106 myDC. It has been shown that CD1c1 myDC can be
isolated in a GMP-approved manner for clinical use in sufﬁ-
cient numbers from a leucopheresis procedure, with a mean
of 13.8 3 109 PBMC and 39.5 3 106 CD1c1 DC obtained
with mean 86% purity.49 The number of myDC which could
be administered per vaccination may be lower than in moDC
clinical trials (which typically administer 5 3 106 to 5 3 107
moDC per vaccination); however if the pre-clinical data on
myDC regarding increased ability to migrate5–7 and enhanced
T-cell stimulatory capacity4 is conﬁrmed, the net “immune
potency” per vaccination may be substantially improved
despite smaller cell numbers. We are therefore embarking on
a pre-clinical feasibility study to establish the necessary sys-
tems for isolation of sufﬁcient myDC from cancer patients,
with the aim of initiating a phase I study of adoptively trans-
ferred myDC treated with p38i.
In cancer patients, circulating myDC are present in sufﬁ-
cient numbers to allow their use as a therapeutic product. As
a group their cytokine secretion after TLR stimulation is nor-
mal and even in individuals with impaired cytokine produc-
tion, p38i restores IL-12 to normal levels. Further
development of p38-inhibited circulating myDC as a thera-
peutic strategy for cancer is warranted.
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